The incretin Glucagon-Like Peptide-1 (GLP-1) was reported to have glucose lowering effects in the late 1980´s, and in 2005, the first GLP1 receptor agonist to treat type 2 diabetes was launched, and more research on this interesting molecule emerges every day. But to make sure your results are accurate and reliable it is of crucial importance to know what form(s) of GLP-1 you are measuring.
HEADQUARTERS IN UPPSALA, SWEDEN:
SE-754 50 UPPSALA, SWEDEN
© COPYRIGHT 2017
PHONE + 46 18 57 00 70
FAX + 46 18 57 00 80